ArticleInternational journal of clinical and experimental pathology2018
A study on the correlation of MyD88 expression with gastric cancer.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Fuelling the Fight from the Gut: Short-Chain Fatty Acids and Dexamethasone Synergise to Suppress Gastric Cancer Cells.Cancers · 2025Article
- The TLR/MyD88 signalling cascade in inflammation and gastric cancer: the immune regulatory network of Helicobacter pylori.Journal of molecular medicine (Berlin, Germany) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe myeloid differentiation factor-88 (MyD88) plays a key role in mediating the innate immune signal transduction of toll-like receptor (TLR) and interleukin-1 (IL-1) family members, and it also participates in the regulation of tumorigenesis in various cancer models Our study sought to determine whether there is any correlation with MyD88 and the development of gastric cancer and, if such a correlation exists, to find out whether it can be used to improve the prognosis of gastric cancer patients. PATIENTS AND
methodsThe expression of MyD88 in 108 cases of gastric cancer specimens, 15 cases of adenoma, and 15 cases of normal mucosa was detected by immunohistochemistry, and the correlations of the MyD88 expression with clinicopathologic changes (including disease-free survival [DFS] and overall survival [OS] were analyzed. The level of MyD88 was detected in well-differentiated MGC-803 and poorly-differentiated BGC-823 cell lines by qPCR and western blot. The expression of MyD88 was then measured by western blot after the treatment of an MyD88 overexpression vector or MyD88 inhibitor. Cell proliferation was determined by overexpression or suppression of MyD88.
resultsIn clinical cases, MyD88 was highly expressed in 23% of patients with gastric cancer as compared to those in normal mucosa and adenoma. There was a significant correlation of MyD88 overexpression with gastric metastasis (
conclusionThis study demonstrates that a high expression of MyD88 is associated with the gastric cancer patients with liver metastasis, and facilitates the proliferation of gastric cancer cells. MyD88 is an independent predictive factor for the poor prognosis of gastric cancer patients, which provides a potential tool for future clinical diagnosis.
Indexed as
Identifiers
31949558PMC6962909W3026277942What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.